Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 31, 2026 07:45 ET | Source: NervGen Pharma Corp.

NervGen Pharma Reports Full Year 2025 Financial Results and Provides Business Updates

Completed End-of-Phase 2 meeting with the FDA; Company expects to provide a regulatory update in early 2Q 2026 and remains on track to initiate a Phase 3 study in chronic tetraplegia in mid-2026....
March 31, 2026 07:30 ET | Source: MiNK Therapeutics

MiNK Therapeutics Reports Q4 and Full Year 2025 Results; Phase 2 Programs Advance with Impactful Non-Dilutive Momentum

ARDS / hypoxemic pneumonia Phase 2 trial initiation 1H 2026; early data by year end; market opportunity of ~200,000–300,000 patients annually in US/EUC-Further Consortium collaboration adds to growing...
March 31, 2026 07:30 ET | Source: Palvella Therapeutics Inc.

Palvella Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Update

New Drug Application (NDA) for QTORIN™ rapamycin for the treatment of microcystic lymphatic malformations (microcystic LMs) on track for planned submission in second half of 2026 Accelerating U.S....
March 31, 2026 07:01 ET | Source: Sixty Degrees Pharmaceuticals

60 Degrees Pharmaceuticals Announces 2025 Annual Results

60 Degrees Pharma (Nasdaq: SXTP) FY25 revenue +65% to $1.0M; improved net loss; continued clinical, commercial, and partnership momentum.
March 31, 2026 07:00 ET | Source: Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Announces Presentation of Phase 1 Data and Outlines Planned Adaptive Phase 2 Field Study of TNX-4800 for the Prevention of Lyme Disease, at the World Vaccine Congress Washington 2026

TNX-4800 is a long-acting anti-Borrelia burgdorferi OspA human monoclonal antibody in development as a single-dose Lyme prophylactic Phase 1 study of TNX-4800 demonstrated safety, tolerability, and...
March 31, 2026 07:00 ET | Source: Agios Pharmaceuticals, Inc.

Agios Advances Mitapivat Toward Potential U.S. Accelerated Approval in Sickle Cell Disease Following Pre-sNDA Meeting with FDA

Agios announces it will pursue U.S. accelerated approval for mitapivat in sickle cell disease
March 31, 2026 06:45 ET | Source: Scynexis

SCYNEXIS Announces $40.0 Million Private Placement

JERSEY CITY, N.J., March 31, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX) (“SCYNEXIS” or the “Company”), a biotechnology company focused on developing innovative new therapies to address...
March 31, 2026 06:40 ET | Source: Scynexis

SCYNEXIS Completes Transformative Acquisition of PXL-770, an innovative, highly selective, direct AMPK activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

PXL-770 (now SCY-770) is a clinical stage, well-characterized oral therapy designed to address the underlying drivers of ADPKD by reducing cyst growth and disease progressionA Phase 2 proof-of-concept...
March 31, 2026 05:00 ET | Source: Oculis Holding AG

Oculis Announces European Medicines Agency PRIME Designation for Privosegtor, Advancing a Potential First‑in‑Class Neuroprotective Candidate for Optic Neuritis

ZUG, Switzerland, March 31, 2026 (GLOBE NEWSWIRE) -- PRIME designation follows recent Breakthrough Therapy designation from the U.S. FDA, underscoring the importance and urgency of addressing optic...
March 31, 2026 04:00 ET | Source: Oculis Holding AG

Oculis Announces European Medicines Agency PRIME Designation for Privosegtor, Advancing a Potential First‑in‑Class Neuroprotective Candidate for Optic Neuritis

PRIME designation follows recent Breakthrough Therapy designation from the U.S. FDA, underscoring the importance and urgency of addressing optic neuritis, a serious condition that can have negative...